Advancing Patient-Centric Insights: Inspire’s Collaboration with the FDA on OUD and PAH
Discover how Inspire’s partnership with the FDA provided actionable insights into opioid use disorder (OUD) and pulmonary arterial hypertension (PAH), improving patient care and reducing stigma.
Patients with opioid use disorder (OUD) and pulmonary arterial hypertension (PAH) face unique challenges, including stigma, treatment barriers, and limited understanding of their lived experiences. Inspire’s case study, Partnering with the FDA to Transform Patient Insights, highlights how Inspire collaborated with the FDA to analyze patient-generated data, uncovering critical insights into these conditions.
In this case study, you’ll learn:
How Inspire’s dual-study approach analyzed 519 comments from OUD patients and 1,813 social media posts from PAH patients, identifying key themes such as withdrawal symptoms, treatment costs, and stigma.
The innovative methods used to integrate social media and archival data, providing a comprehensive view of patient experiences.
How these insights highlighted unmet needs, such as managing treatment side effects and reducing stigma, to inform patient-centric strategies.
The framework developed for leveraging unstructured data sources to enhance healthcare research and decision-making.
Discover how Inspire’s collaboration with the FDA is transforming patient insights and driving better outcomes for OUD and PAH patients.